Showing results (361-370 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|December 4, 2015
Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulinAndrew AhmannDrugs in Context|February 8, 2018
Lipocrinology - the relationship between lipids and endocrine functionSanjay Kalra, Gagan PriyaDrugs in Context|November 24, 2017
Synchronous GISTs associated with multiple sporadic tumors: a case reportDanila Comandini, Azzurra Damiani, Alessandro PastorinoDrugs in Context|November 24, 2017
Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)Neon Brooks, Mario Campone, Silvia Paddock, et al.Drugs in Context|January 19, 2018
Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetesMargarita SaizSatjes, Francisco Javier Martinez-MartinDrugs in Context|May 1, 2018
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbilEdgardo Kaplinsky, Gordon MallarkeyDrugs in Context|September 6, 2018
The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathyYue Zhao, Rishi P SinghDrugs in Context|September 15, 2018
Spectral Doppler and automated software-guided ultrasound assessment of bilateral common carotid intima-media thickness in spondyloarthritis: is there a correlation with clinical findings?José Alexandre Mendonça, Beatriz Bisetto de Andrade, José Luis Braga de Aquino, et al.Drugs in Context|September 15, 2018
Primary genetic disorders affecting high density lipoprotein (HDL)Constantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.Drugs in Context|September 21, 2016
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondElif A OralPageof 56